What is the step‑wise treatment algorithm for an adult with chronic vitamin D deficiency, including loading and maintenance dosing of cholecalciferol (vitamin D3) and dose adjustments for obesity, malabsorption, chronic kidney disease stage 4–5, and interacting medications?

Chronic Vitamin D Deficiency Treatment Algorithm

Step 1: Confirm Deficiency and Assess Severity

Measure serum 25-hydroxyvitamin D [25(OH)D] to classify deficiency severity:

• Severe deficiency: <10–12 ng/mL 1
• Deficiency: <20 ng/mL 1
• Insufficiency: 20–30 ng/mL 1
• Target for treatment: ≥30 ng/mL for anti-fracture efficacy 1

Check baseline serum calcium, phosphorus, and parathyroid hormone (PTH) to rule out hypocalcemia and establish safety parameters before initiating high-dose therapy 1.

---

Step 2: Loading Phase – Correct the Deficiency

Standard Loading Regimen (Most Patients)

Administer cholecalciferol (vitamin D3) 50,000 IU once weekly for 8–12 weeks 1:

• Use 8 weeks for moderate deficiency (10–20 ng/mL) 1
• Use 12 weeks for severe deficiency (<10 ng/mL) 1
• Cholecalciferol (D3) is strongly preferred over ergocalciferol (D2) because it maintains serum levels longer and has superior bioavailability, especially with intermittent dosing 1

Expected response: Each 1,000 IU daily raises 25(OH)D by approximately 10 ng/mL; 50,000 IU weekly (≈7,000 IU/day) should increase levels by 40–70 ng/mL over 8–12 weeks 1.

Dose Adjustments for Special Populations

Obesity (BMI ≥30 kg/m²)

Vitamin D is sequestered in adipose tissue, requiring higher doses 1:

• Use 50,000 IU twice weekly (100,000 IU/week total) for 8–12 weeks 2
• Alternative: 7,000 IU daily for prolonged maintenance without monitoring 2
• Calculate individualized loading dose using: dose (IU) = 40 × (75 – baseline 25(OH)D) × body weight (kg) 3

Malabsorption Syndromes (Post-Bariatric Surgery, IBD, Celiac Disease, Pancreatic Insufficiency, Short Bowel Syndrome)

Oral absorption is impaired; intramuscular (IM) administration is preferred 1:

• IM cholecalciferol 50,000 IU once weekly for 8–12 weeks achieves mean 25(OH)D of 49.5 ng/mL vs. 30.9 ng/mL with oral therapy 1
• Persistent deficiency occurs in only 3.7% with IM vs. 39% with oral 1
• If IM unavailable: escalate oral to 50,000 IU 2–3 times weekly or 4,000–5,000 IU daily for 2 months 1, 2
• Post-bariatric surgery minimum maintenance: 2,000 IU daily 1

Chronic Kidney Disease Stage 4–5 (GFR <30 mL/min/1.73m²)

Use standard nutritional vitamin D (cholecalciferol or ergocalciferol), NOT active analogs 1:

• 50,000 IU weekly for 12 weeks (same as general population) 1
• Monitor serum calcium and phosphorus every 3 months during treatment 1
• Discontinue immediately if calcium >10.2 mg/dL (2.54 mmol/L) 1
• Never use calcitriol, alfacalcidol, doxercalciferol, or paricalcitol for nutritional deficiency—they bypass regulation and increase hypercalcemia risk 1

Chronic Liver Disease (Cirrhosis, Cholestasis)

Hepatic 25-hydroxylation is impaired only in severe disease 4:

• Consider calcifediol (25-hydroxyvitamin D) 10–20 mcg daily if cholecalciferol fails, as it bypasses hepatic hydroxylation 5
• Standard cholecalciferol 50,000 IU weekly is appropriate for mild-moderate liver disease 1

Medications Affecting Vitamin D Metabolism (Anticonvulsants, Glucocorticoids, Antiretrovirals, Orlistat)

These drugs accelerate vitamin D catabolism 1:

• Use 50,000 IU twice weekly (100,000 IU/week) for 8–12 weeks 2
• Maintenance: 2,000–4,000 IU daily 1

---

Step 3: Maintenance Phase – Sustain Optimal Levels

After completing the loading phase, transition to maintenance dosing to keep 25(OH)D ≥30 ng/mL 1:

Standard Maintenance (Most Patients)

• 800–2,000 IU daily 1
• Alternative: 50,000 IU once monthly (≈1,600 IU/day) 1

Obesity

• 2,000–4,000 IU daily or 7,000 IU daily without monitoring 2
• Alternative: 30,000 IU weekly 2

Malabsorption

• IM cholecalciferol 50,000 IU every 2–4 months 1
• If IM unavailable: 2,000–5,000 IU daily 1, 2

CKD Stage 4–5

• 800–2,000 IU daily with calcium/phosphorus monitoring every 3 months 1

Elderly (≥65 years)

• Minimum 800 IU daily; higher doses of 700–1,000 IU daily reduce falls by 19% and fractures by 18–20% 1

Drug Interactions

• 2,000–4,000 IU daily 1

---

Step 4: Monitoring Protocol

Recheck 25(OH)D 3 months after starting maintenance therapy to confirm levels ≥30 ng/mL 1:

• If <30 ng/mL: increase maintenance dose by 1,000–2,000 IU daily 1
• If 30–44 ng/mL: continue current dose 1
• If >100 ng/mL: discontinue and recheck in 3 months 1

Once stable, monitor annually 1.

For intermittent dosing (weekly/monthly), measure 25(OH)D immediately before the next scheduled dose 1.

---

Step 5: Essential Co-Interventions

Ensure adequate calcium intake of 1,000–1,500 mg daily (diet + supplements) 1:

• Divide calcium supplements into doses ≤600 mg for optimal absorption 1
• Calcium is necessary for vitamin D to exert bone-protective effects 1

---

Critical Safety Thresholds

• Upper safety limit for 25(OH)D: 100 ng/mL 1
• Safe daily dose: up to 4,000 IU 1
• Toxicity threshold: >10,000 IU daily or 25(OH)D >100 ng/mL 1
• Avoid single mega-doses >300,000 IU—they increase falls and fractures 1
• Monitor calcium/phosphorus every 3 months during high-dose therapy in CKD 1

---

Common Pitfalls

• Do not use active vitamin D analogs (calcitriol, alfacalcidol) for nutritional deficiency—they cause hypercalcemia 1
• Do not measure 25(OH)D earlier than 3 months after starting therapy—levels need time to plateau 1
• Do not rely on 600–800 IU daily to correct deficiency—it takes months and is insufficient for high-risk groups 1
• Do not ignore malabsorption—oral therapy fails in 39% of post-bariatric patients; use IM 1
• Do not exceed 4,000 IU daily long-term without monitoring 1